Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
5(83.3%)
Phase 3
1(16.7%)
6Total
N/A(5)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT03255057Not ApplicableTerminated

Extracorporeal CO2 Removal With the Hemolung RAS for Mechanical Ventilation Avoidance During Acute Exacerbation of COPD

Role: lead

NCT02086084Not ApplicableCompleted

ECCO2R as an Adjunct to NIV in AECOPD

Role: collaborator

NCT01021605Not ApplicableCompleted

Feasibility Study of the Hemolung Respiratory Assist System (Germany)

Role: lead

NCT01855815Unknown

Hemolung RAS Registry Program

Role: lead

NCT02586948Not ApplicableCompleted

Physiological Study of Minimally Invasive ECCO2R in Exacerbations of COPD Requiring Invasive Mechanical Ventilation

Role: collaborator

NCT00987740Not ApplicableCompleted

Feasibility Study of the Hemolung Respiratory Assist System

Role: lead

NCT00288964Phase 3Withdrawn

Use of the Hattler Respiratory Assist Catheter in Severe Respiratory Failure

Role: lead

All 7 trials loaded